The humoral immune response to HCV: Understanding is key to vaccine development

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Cashman, Siobhán B ^a   Marsden, Brian D ^a,b   Dustin, Lynn B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acute infection; Chronic infection; HCV; HCV E2 glycoprotein; Monoclonal antibodies; Neutralizing antibodies; Viral antibodies

Indexed keywords

CD71 ANTIGEN; CD81 ANTIGEN; CLAUDIN 1; EPITOPE; GENOMIC RNA; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS VACCINE; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY; SCAVENGER RECEPTOR BI; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS REACTION; DISEASE COURSE; ESCAPE BEHAVIOR; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PERSISTENT VIRUS INFECTION; REVIEW; VACCINATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

EID: 84919382829     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00550     Document Type: Review

References (163)

1. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 29(Suppl 1):89-99. doi: 10.1111/j.1478-3231.2008.01927.x
2. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 10:553-62. doi:10.1038/nrgastro.2013.107
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (2013) 57:1333-42. doi:10.1002/hep.26141
4. Manns MP, Mchutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358:958-65. doi:10.1016/S0140-6736(01)06102-5
5. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 140:346-55. doi:10.7326/0003-4819-140-5-200403020-00010
6. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 13:535-42. doi:10.1038/nri3463
7. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 19:837-49. doi:10.1038/nm.3248
8. Tse MT. All-oral HCV therapies near approval. Nat Rev Drug Discov (2013) 12:409-11. doi:10.1038/nrd4036
9. Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 12:595-610. doi:10.1038/nrd4050
10. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 19:850-8. doi:10.1038/nm.3184
11. Wang Y, Keck ZY, Foung SK. Neutralizing antibody response to hepatitis C virus. Viruses (2011) 3:2127-45. doi:10.3390/v3112127
12. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 59:318-27. doi:10.1002/hep.26744
13. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 337:183-6. doi:10.1126/science.1225416
14. Courouce AM, Bouchardeau F, Girault A, Le Marrec N. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet (1994) 343:853-4. doi:10.1016/S0140-6736(94)92054-0
15. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 194:1395-406. doi:10.1084/jem.194.10.1395
16. Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, et al. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology (2005) 128:1056-66. doi:10.1053/j.gastro.2005.01.049
17. Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, et al. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 41:667-75. doi:10.1086/432478
18. Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V, et al. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol (2005) 42:646-51. doi:10.1016/j.jhep.2004.12.027
19. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 436:946-52. doi:10.1038/nature04079
20. Callendret B, Walker C. A siege of hepatitis: immune boost for viral hepatitis. Nat Med (2011) 17:252-3. doi:10.1038/nm0311-252
21. Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev (2012) 36:663-83. doi:10.1111/j.1574-6976.2011.00319.x
22. Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection-tipping the balance. J Leukoc Biol (2014) 96:535-48. doi:10.1189/jlb.4RI0214-126R
23. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity (2014) 40:13-24. doi:10.1016/j.immuni.2013.12.010
24. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 99:15661-8. doi:10.1073/pnas.202608299
25. Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 127:924-36. doi:10.1053/j.gastro.2004.06.015
26. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 119:1745-54. doi:10.1172/JCI39133
27. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 19:859-68. doi:10.1038/nm.3251
28. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 10:439-49. doi:10.1016/S1074-7613(00)80044-8
29. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 101:10149-54. doi:10.1073/pnas.0403519101
30. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2008) 14:25-7. doi:10.1038/nm1698
31. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2010) 138:315-24. doi:10.1053/j.gastro.2009.09.017
32. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 109:6205-10. doi:10.1073/pnas.1114927109
33. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology (2014) 59:2140-51. doi:10.1002/hep.27013
34. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol (2013) 31:705-42. doi:10.1146/annurev-immunol-032712-095916
35. Michalak JP, Wychowski C, Choukhi A, Meunier JC, Ung S, Rice CM, et al. Characterization of truncated forms of hepatitis C virus glycoproteins. J Gen Virol (1997) 78(Pt 9):2299-306.
36. Liu J, Zhu LX, Kong YY, Li GD, Wang Y. Purification and application of C-terminally truncated hepatitis C virus E1 proteins expressed in Escherichia coli. World J Gastroenterol (2005) 11:503-7. Available from: http://www.wjgnet.com/1007-9327/11/503.asp
37. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol (2005) 79:8400-9. doi:10.1128/JVI.79.13.8400-8409.2005
38. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science (1998) 282:938-41. doi:10.1126/science.282.5390.938
39. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 21:5017-25. doi:10.1093/emboj/cdf529
40. Evans MJ, Von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 446:801-5. doi:10.1038/nature05654
41. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, De Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 457:882-6. doi:10.1038/nature07684
42. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 17:589-95. doi:10.1038/nm.2341
43. Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 18:281-5. doi:10.1038/nm.2581
44. Martin DN, Uprichard SL. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A (2013) 110:10777-82. doi:10.1073/pnas.1301764110
45. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science (2013) 342:1090-4. doi:10.1126/science.1243876
46. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature (2014) 509:381-4. doi:10.1038/nature13117
47. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol (1993) 67:3923-30.
48. van Doorn LJ, Capriles I, Maertens G, Deleys R, Murray K, Kos T, et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol (1995) 69:773-8.
49. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 288:339-44. doi:10.1126/science.288.5464.339
50. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 136:2377-86. doi:10.1053/j.gastro.2009.02.080
51. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 278:41624-30. doi:10.1074/jbc.M305289200
52. Vieyres G, Dubuisson J, Patel AH. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J Gen Virol (2011) 92:494-506. doi:10.1099/vir.0.028092-0
53. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 100:14199-204. doi:10.1073/pnas.2335981100
54. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 100:7271-6. doi:10.1073/pnas.0832180100
55. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology (1996) 223:409-12. doi:10.1006/viro.1996.0497
56. Sabo MC, Luca VC, Ray SC, Bukh J, Fremont DH, Diamond MS. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology (2012) 422:174-84. doi:10.1016/j.virol.2011.10.023
57. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 73:6235-44.
58. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 104:8449-54. doi:10.1073/pnas.0703039104
59. Dhillon S, Witteveldt J, Gatherer D, Owsianka AM, Zeisel MB, Zahid MN, et al. Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 84:5494-507. doi:10.1128/JVI.02153-09
60. Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, et al. Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol (2011) 85:10451-63. doi:10.1128/JVI.05259-11
61. Tarr AW, Owsianka AM, Timms JM, Mcclure CP, Brown RJ, Hickling TP, et al. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology (2006) 43:592-601. doi:10.1002/hep.21088
62. Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, et al. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 86:12923-32. doi:10.1128/JVI.02052-12
63. Keck ZY, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, et al. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog (2014) 10:e1004297. doi:10.1371/journal.ppat.1004297
64. Tarr AW, Owsianka AM, Jayaraj D, Brown RJ, Hickling TP, Irving WL, et al. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol (2007) 88:2991-3001. doi:10.1099/vir.0.83065-0
65. Kachko A, Kochneva G, Sivolobova G, Grazhdantseva A, Lupan T, Zubkova I, et al. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles. Vaccine (2011) 30:69-77. doi:10.1016/j.vaccine.2011.10.045
66. Krey T, D'Alayer J, Kikuti CM, Saulnier A, Damier-Piolle L, Petitpas I, et al. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog (2010) 6:e1000762. doi:10.1371/journal.ppat.1000762
67. Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF, Duverlie G, et al. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. J Virol (2014) 88:10584-97. doi:10.1128/JVI.01402-14
68. Sourisseau M, Michta ML, Zony C, Israelow B, Hopcraft SE, Narbus CM, et al. Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog (2013) 9:e1003244. doi:10.1371/journal.ppat.1003244
69. Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 139:e951-4. doi:10.1053/j.gastro.2010.05.073
70. Xiao F, Fofana I, Heydmann L, Barth H, Soulier E, Habersetzer F, et al. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog (2014) 10:e1004128. doi:10.1371/journal.ppat.1004128
71. Wahid A, Dubuisson J. Virus-neutralizing antibodies to hepatitis C virus. J Viral Hepat (2013) 20:369-76. doi:10.1111/jvh.12094
72. Leroux-Roels G, Esquivel CA, Deleys R, Stuyver L, Elewaut A, Philippe J, et al. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa. Hepatology (1996) 23:8-16. doi:10.1053/jhep.1996.v23.pm0008550052
73. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 104:6025-30. doi:10.1073/pnas.0607026104
74. Luo K, Li S, Jiang L, Zuo T, Qing J, Shi X, et al. Combinatorial library based profiling of antibody response against hepatitis C virus in human. J Gen Virol (2014). doi:10.1099/vir.0.069278-0
75. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med (2011) 3:94ra71. doi:10.1126/scitranslmed.3002330
76. Keck ZY, Sung VM, Perkins S, Rowe J, Paul S, Liang TJ, et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol (2004) 78:7257-63. doi:10.1128/JVI.78.13.7257-7263.2004
77. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J Virol (2008) 82:966-73. doi:10.1128/JVI.01872-07
78. Brazzoli M, Helenius A, Foung SK, Houghton M, Abrignani S, Merola M. Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology (2005) 332:438-53. doi:10.1016/j.virol.2004.11.034
79. Lavillette D, Pecheur EI, Donot P, Fresquet J, Molle J, Corbau R, et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol (2007) 81:8752-65. doi:10.1128/JVI.02642-06
80. Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol (2013) 11:688-700. doi:10.1038/nrmicro3098
81. Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol (2007) 81:13783-93. doi:10.1128/JVI.01091-07
82. Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, Rice WJ, et al. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci U S A (2013) 110:9505-10. doi:10.1073/pnas.1307527110
83. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 91:7792-6. doi:10.1073/pnas.91.16.7792
84. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol (1998) 72:3827-36.
85. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 197:633-42. doi:10.1084/jem.20021756
86. Tarr AW, Owsianka AM, Szwejk A, Ball JK, Patel AH. Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins. Methods Mol Biol (2007) 379:177-97. doi:10.1007/978-1-59745-393-6_13
87. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science (2005) 309:623-6. doi:10.1126/science.1114016
88. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 11:791-6. doi:10.1038/nm0805-905b
89. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 102:9294-9. doi:10.1073/pnas.0503596102
90. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology (2009) 49:364-77. doi:10.1002/hep.22673
91. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 13:34-41. doi:10.1111/j.1365-2893.2005.00651.x
92. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 200:1216-26. doi:10.1086/605947
93. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 461:798-801. doi:10.1038/nature08463
94. Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis (2013) 56:405-13. doi:10.1093/cid/cis921
95. Grebely J, Page K, Sacks-Davis R, Van Der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2014) 59:109-20. doi:10.1002/hep.26639
96. Lau GK, Lesniewski R, Johnson RG, Davis GL, Lau JY. Immunoglobulin M and A antibodies to hepatitis C core antigen in chronic hepatitis C virus infection. J Med Virol (1994) 44:1-4. doi:10.1002/jmv.1890440102
97. Yamaguchi N, Tokushige K, Yamauchi K, Hayashi N. Humoral immune response in Japanese acute hepatitis patients with hepatitis C virus infection. Can J Gastroenterol (2000) 14:593-8.
98. Chen PJ, Wang JT, Hwang LH, Yang YH, Hsieh CL, Kao JH, et al. Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection. Proc Natl Acad Sci U S A (1992) 89:5971-5. doi:10.1073/pnas.89.13.5971
99. Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, et al. Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat (2002) 9:429-37. doi:10.1046/j.1365-2893.2002.00369.x
100. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 321:1494-500. doi:10.1056/NEJM198911303212202
101. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol (2007) 25:71-99. doi:10.1146/annurev.immunol.25.022106.141602
102. Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology (1999) 116:135-43. doi:10.1016/S0016-5085(99)70237-4
103. Steinmann D, Barth H, Gissler B, Schurmann P, Adah MI, Gerlach JT, et al. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 78:9030-40. doi:10.1128/JVI.78.17.9030-9040.2004
104. Kaplan DE, Sugimoto K, Newton K, Valiga ME, Ikeda F, Aytaman A, et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2007) 132:654-66. doi:10.1053/j.gastro.2006.11.044
105. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med (2000) 6:578-82. doi:10.1038/75063
106. Semmo N, Lucas M, Krashias G, Lauer G, Chapel H, Klenerman P. Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. Blood (2006) 107:4570-1. doi:10.1182/blood-2005-11-4522
107. Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol (1999) 73:1118-26.
108. Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol (2001) 101:284-8. doi:10.1006/clim.2001.5132
109. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol (2002) 76:6586-95. doi:10.1128/JVI.76.13.6586-6595.2002
110. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis (2004) 189:1846-55. doi:10.1086/383279
111. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis (2012) 205:763-71. doi:10.1093/infdis/jir835
112. Esteban-Riesco L, Depaulis F, Moreau A, Bacq Y, Dubois F, Goudeau A, et al. Rapid and sustained autologous neutralizing response leading to early spontaneous recovery after HCV infection. Virology (2013) 444:90-9. doi:10.1016/j.virol.2013.05.037
113. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med (1994) 331:1607-11. doi:10.1056/NEJM199412153312402
114. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol (2008) 83:59-62. doi:10.1002/ajh.21022
115. Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, et al. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One (2013) 8:e80216. doi:10.1371/journal.pone.0080216
116. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology (2001) 33:1479-87. doi:10.1053/jhep.2001.24371
117. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 93:15394-9. doi:10.1073/pnas.93.26.15394
118. Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, et al. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 8:e1002895. doi:10.1371/journal.ppat.1002895
119. Yu MY, Bartosch B, Zhang P, Guo ZP, Renzi PM, Shen LM, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 101:7705-10. doi:10.1073/pnas.0402458101
120. Yu MW, Mason BL, Guo ZP, Tankersley DL, Nedjar S, Mitchell FD, et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet (1995) 345:1173-4. doi:10.1016/S0140-6736(95)91002-6
121. Healey CJ, Sabharwal NK, Daub J, Davidson F, Yap PL, Fleming KA, et al. Outbreak of acute hepatitis C following the use of anti-hepatitis C virus - screened intravenous immunoglobulin therapy. Gastroenterology (1996) 110:1120-6. doi:10.1053/gast.1996.v110.pm8613001
122. Bresee JS, Mast EE, Coleman PJ, Baron MJ, Schonberger LB, Alter MJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA (1996) 276:1563-7.
123. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine (2008) 26:6266-73. doi:10.1016/j.vaccine.2008.09.056
124. Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology (2010) 139:965-74. doi:10.1053/j.gastro.2010.05.077
125. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis (2011) 204:1186-90. doi:10.1093/infdis/jir511
126. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 28:6367-73. doi:10.1016/j.vaccine.2010.06.084
127. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 8:e59776. doi:10.1371/journal.pone.0059776
128. Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 19:869-78. doi:10.1038/nm.3183
129. Xue J, Zhu H, Chen Z. Therapeutic vaccines against hepatitis C virus. Infect Genet Evol (2014) 22:120-9. doi:10.1016/j.meegid.2014.01.008
130. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 282:103-7. doi:10.1126/science.282.5386.103
131. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2:30ra32. doi:10.1126/scitranslmed.3000544
132. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2007) 132:667-78. doi:10.1053/j.gastro.2006.12.008
133. Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol (2010) 84:5067-77. doi:10.1128/JVI.02265-09
134. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 84:5751-63. doi:10.1128/JVI.02200-09
135. Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari FV, et al. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 97:13318-23. doi:10.1073/pnas.230453597
136. Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, et al. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol (2011) 85:2224-34. doi:10.1128/JVI.01594-10
137. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology (1998) 27:223-7. doi:10.1002/hep.510270134
138. Gaud U, Langer B, Petropoulou T, Thomas HC, Karayiannis P. Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. J Med Virol (2003) 69:350-6. doi:10.1002/jmv.10296
139. Lee WM, Polson JE, Carney DS, Sahin B, Gale M Jr. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis (2005) 192:1088-92. doi:10.1086/432917
140. Helle F, Duverlie G, Dubuisson J. The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses (2011) 3:1909-32. doi:10.3390/v3101909
141. Whidby J, Mateu G, Scarborough H, Demeler B, Grakoui A, Marcotrigiano J. Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J Virol (2009) 83:11078-89. doi:10.1128/JVI.00800-09
142. Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol (2007) 81:8072-9. doi:10.1128/JVI.00459-07
143. Helle F, Goffard A, Morel V, Duverlie G, Mckeating J, Keck ZY, et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 81:8101-11. doi:10.1128/JVI.00127-07
144. Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, Descamps V, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol (2010) 84:11905-15. doi:10.1128/JVI.01548-10
145. Bartenschlager R, Penin F, Lohmann V, Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol (2011) 19:95-103. doi:10.1016/j.tim.2010.11.005
146. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 76:6919-28. doi:10.1128/JVI.76.14.6919-6928.2002
147. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, Mckeating JA, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 103:3805-9. doi:10.1073/pnas.0511218103
148. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 82:12020-9. doi:10.1128/JVI.01569-08
149. Meunier JC, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU. Apolipoprotein c1 association with hepatitis C virus. J Virol (2008) 82:9647-56. doi:10.1128/JVI.00914-08
150. Merz A, Long G, Hiet MS, Brugger B, Chlanda P, Andre P, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem (2011) 286:3018-32. doi:10.1074/jbc.M110.175018
151. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem (2006) 281:18285-95. doi:10.1074/jbc.M602706200
152. Di Lorenzo C, Angus AG, Patel AH. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 3:2280-300. doi:10.3390/v3112280
153. Dreux M, Boson B, Ricard-Blum S, Molle J, Lavillette D, Bartosch B, et al. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J Biol Chem (2007) 282:32357-69. doi:10.1074/jbc.M705358200
154. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 47:17-24. doi:10.1002/hep.21959
155. Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 90:48-58. doi:10.1099/vir.0.006700-0
156. Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2011) 85:596-605. doi:10.1128/JVI.01592-10
157. Catanese MT, Loureiro J, Jones CT, Dorner M, Von Hahn T, Rice CM. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol (2013) 87:8282-93. doi:10.1128/JVI.01102-13
158. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, Mihalik K, et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A (2009) 106:7537-41. doi:10.1073/pnas.0902749106
159. Lapierre P, Troesch M, Alvarez F, Soudeyns H. Structural basis for broad neutralization of hepatitis C virus quasispecies. PLoS One (2011) 6:e26981. doi:10.1371/journal.pone.0026981
160. Duan H, Kachko A, Zhong L, Struble E, Pandey S, Yan H, et al. Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein. J Virol (2012) 86:12686-94. doi:10.1128/JVI.00994-12
161. Sautto G, Mancini N, Diotti RA, Solforosi L, Clementi M, Burioni R. Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral Res (2012) 96:82-9. doi:10.1016/j.antiviral.2012.07.013
162. Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, Mckeating JA, Irving WL, et al. Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2012) 86:2739-49. doi:10.1128/JVI.06492-11
163. Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, et al. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2013) 87:37-51. doi:10.1128/JVI.01941-12